Botanix
Ground Floor, 16 Ord Street
West Perth
Western Australia
6005
Tel: 61 417 382 391
Fax: 61 2 9237 2800
Website: http://www.botanixpharma.com/
Email: info@botanixpharma.com
25 articles about Botanix
-
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
7/21/2023
Fresh Tracks Therapeutics, Inc. announced it has entered into an amendment to its Asset Purchase Agreement with Botanix Pharmaceuticals Limited and its subsidiary, Botanix SB Inc., to sell its rights to future event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. for $8.25 million.
-
Brickell Biotech Announces Sale of Sofpironium Bromide to Botanix Pharmaceuticals
5/3/2022
Brickell Biotech, Inc. announced that it has signed and closed a definitive asset purchase agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, whereby Botanix has acquired the Company’s rights to sofpironium bromide, a retrometabolically-designed new chemical entity that belongs to a class of medications called anticholinergics.
-
Botanix receives commitments for A$40m in US-led institutional placement and announces appointment of key US management executives
8/1/2019
Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.
-
Botanix Receives Commitments for A$40m in US-Led Institutional Placement and Announces Appointment of Key US Management Executives
8/1/2019
Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.
-
Vince Ippolito appointed as Botanix Executive Chairman
7/18/2019
Mr Vince Ippolito, a US-based dermatology industry leader with over 30 years of pharmaceuticals experience, appointed as Executive Chairman of Botanix Pharmaceuticals
-
Botanix’s antimicrobial platform addresses significant global threat
7/15/2019
New data has shown that a new drug candidate from Botanix’s cannabidiol antimicrobial platform has potent activity against hypervirulent strains of the bacteria Clostridium difficile
-
New BTX 1801 data presented at ASM Microbe 2019
6/24/2019
Botanix collaborator Dr Mark Blaskovich of the University of Queensland presented new antimicrobial data at ASM Microbe 2019, highlighting cannabidiol as a remarkably active Gram-Positive antibiotic
-
BTX 1801 kills superbugs without resistance: world-first study
6/20/2019
Clinical stage cannabinoid company Botanix Pharmaceuticals Limited is pleased to announce new data from studies recently conducted with its antimicrobial product BTX 1801.
-
Dermatology industry leader joins Botanix
5/20/2019
Appointment of Mr Vince Ippolito, a US-based dermatology industry leader with over 30 years of pharmaceuticals experience as President of Botanix
-
Appointment of Executive Director, Dr Michael Thurn
2/12/2019
Philadelphia PA and Sydney Australia, 12 February 2019: Medical dermatology company Botanix Pharmaceuticals Limited is pleased to announce the appointment of Dr Michael Thurn, Head of Australian Operations, as Executive Director.
-
Botanix receives A$4.6m R&D Tax Incentive refund
11/23/2018
Botanix receives R&D Tax Incentive refund of A$4.6m
-
Botanix treats first patient in BTX 1308 psoriasis patient study
11/7/2018
Botanix has treated the first patient in its BTX 1308 psoriasis Phase 1b patient study
-
Botanix secures ethics approval for BTX 1308 Psoriasis patient study
9/27/2018
Botanix has received Human Research Ethics Committee approval to commence the planned BTX 1308 psoriasis Phase 1b patient study
-
Botanix presents at European Dermatology Conference
9/14/2018
Botanix will be presenting at the 27th EADV Congress in Paris, France
-
Botanix BTX 1503 Clinical Trial Update
9/13/2018
BTX 1503 acne Phase 2 clinical trial currently underway across US and Australian sites with data expected in mid-CY2019
-
Botanix Pharmaceuticals Preliminary Final Report
9/7/2018
Successfully completed the BTX 1530 Phase 1b acne patient and advanced into Phase 2 clinical development in June 2108
-
FDA clears development path for BTX 1204
9/7/2018
Botanix held a Pre-IND Meeting with the FDA for the BTX 1204 atopic dermatitis product
-
BTX 1204 Atopic Dermatitis Study Results Presentation
6/7/2018
Medical dermatology company Botanix Pharmaceuticals Limited is pleased to release a presentation containing supplementary information on the BTX 1204 atopic dermatitis Phase lb study results.
-
Botanix Announces Successful Pilot Study For BTX 1701 Facial Cleanser
6/8/2017
-
Botanix Commences First Clinical Study For BTX 1503
5/8/2017